Screener
Supernus Pharmaceuticals SUPN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Purchases of marketable securities | (78,438) | (118,557) |
| Maturities of marketable securities | 59,220 | 156,201 |
| Purchases of property and equipment | — | (327) |
| Net cash provided by (used in) investing activities | (19,218) | 37,317 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock | 13,670 | 2,042 |
| Employee taxes paid related to net share settlement of equity awards | (4,555) | (3,341) |
| Payment of contingent consideration | — | (20,100) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's investing cash flow?
- Supernus Pharmaceuticals (SUPN) reported investing cash flow of -$19.22M in Q1 2026.
- How has Supernus Pharmaceuticals's investing cash flow changed year-over-year?
- Supernus Pharmaceuticals's investing cash flow decreased by 151.5% year-over-year, from $37.32M to -$19.22M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Supernus Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude